Table 4 Reasons for discontinuing, switching, or adding/reducing therapy (2004–2015)
| Â | TNFi monotherapy | Other biologic monotherapya | csDMARD monotherapy | TNFi + csDMARD combination therapy | Other Biologica + csDMARD combination therapy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | N = 770 | Â | Â | N = 369 | Â | Â | N = 2982 | Â | Â | N = 3022 | Â | Â | N = 884 | Â | Â |
Factors (number of factors) | Disc. (181) | Swit. (799) | Add (383) | Disc. (97) | Swit. (258) | Add (117) | Disc. (503) | Swit. (2030) | Add (1375) | Disc. (270) | Swit. (2945) | Reduction (1567) | Disc. (68) | Swit.(762) | Reduction (438) |
Number of patients with ≥ 1 reason, n | 74 | 265 | 83 | 39 | 100 | 25 | 139 | 654 | 312 | 116 | 954 | 640 | 24 | 1227 | 165 |
Total number of reasons | 84 | 390 | 97 | 46 | 129 | 32 | 154 | 821 | 385 | 126 | 1456 | 694 | 27 | 426 | 192 |
 Doing well,b n (%) | 3 (3.6) | 5 (1.3) | 1 (1.0) | 2 (4.3) | 3 (2.3) | 0 (0) | 14 (9.1) | 19 (2.3) | 6 (1.6) | 10 (7.9) | 19 (1.3) | 55 (7.9) | 2 (7.4) | 4 (0.9) | 2 (1.0) |
 Lack of efficacy,c n (%) | 17 (20.2) | 184 (47.2) | 16 (16.5) | 16 (34.8) | 69 (53.5) | 8 (25.0) | 19 (12.3) | 232 (28.3) | 61 (15.8) | 28 (22.2) | 615 (42.2) | 183 (26.4) | 7 (25.9) | 207 (48.6) | 71 (37.0) |
 Other reasons,d n (%) | 23 (27.4) | 96 (24.6) | 61 (62.9) | 7 (15.2) | 20 (15.5) | 15 (46.9) | 34 (22.1) | 196 (23.9) | 236 (61.3) | 27 (21.4) | 360 (24.7) | 186 (26.8) | 5 (18.5) | 89 (20.9) | 42 (21.9) |
 Side effects,e n (%) | 23 (27.4) | 61 (15.6) | 9 (9.3) | 10 (21.7) | 18 (14.0) | 3 (9.4) | 55 (35.7) | 250 (30.5) | 28 (7.3) | 27 (21.4) | 266 (18.3) | 142 (20.5) | 8 (29.6) | 80 (18.8) | 40 (20.8) |
 Social reasons,f n (%) | 18 (21.4) | 44 (11.3) | 10 (10.3) | 11 (23.9) | 19 (14.7) | 6 (18.8) | 32 (20.8) | 124 (15.1) | 54 (14) | 34 (27.0) | 196 (13.5) | 128 (18.4) | 5 (18.5) | 46 (10.8) | 37 (19.3) |